
- Oncology NEWS International Vol 4 No 4
- Volume 4
- Issue 4
Gemzar Gets Treatment IND for Advanced Pancreatic Cancer
INDIANAPOLIS--Eli Lilly and Company has received FDA approval to provide gemcitabine (Gemzar) to advanced pancreatic cancer patients through a Treatment Investigational New Drug program.
INDIANAPOLIS--Eli Lilly and Company has received FDA approvalto provide gemcitabine (Gemzar) to advanced pancreatic cancerpatients through a Treatment Investigational New Drug program.
The agent will be provided free of charge to patients who arenot candidates for surgery and who meet certain medical eligibilitycriteria. Patients may have been previously untreated or havehad one prior chemotherapy regimen. Physicians may call 1-800-621-7111for more information about the Treatment IND.
Articles in this issue
over 30 years ago
First Results of Avicidin Trialsover 30 years ago
Chemo Patients Often Develop Menstrual Irregularitiesover 30 years ago
Growth Factor Receptor Blockade Moving From Laboratory to Clinicover 30 years ago
Controlled-Release AZT Gets FDA Go-Ahead for New Drug Investigationover 30 years ago
Vinorelbine Plus Chemo Promising in Advanced Diseaseover 30 years ago
Bone Substudy a Part of Tamoxifen Prevention Trialover 30 years ago
Ultrasound Breast Screens Useful in Selected Womenover 30 years ago
New Roles Forecast for Endocrine Therapyover 30 years ago
Antisense Drug Against BCL-2 Effective in Animal Cancer Modelsover 30 years ago
Anticancer Drugs From Zeneca in Regulatory Phase of DevelopmentNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.